|
Yale Comprehensive Cancer Center Support Grant
|
2P30CA016359-34
|
$2,531,005
|
$50,620
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-34S1
|
$75,000
|
$1,500
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-16
|
$320,126
|
$25,610
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Wnt Signaling and Secreted Frizzled-Related Proteins
|
ZIA BC 010251
|
$318,862
|
$63,772
|
Rubin, Jeffrey
|
CCR (NCI)
|
|
WESTERN ONCOLOGY RESEARCH CONSORTIUM
|
5U10CA045377-27
|
$589,569
|
$5,896
|
Conlin, Alison
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-29
|
$612,504
|
$6,125
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
3R01CA109860-09S1
|
$88,962
|
$88,962
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-09
|
$308,789
|
$308,789
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
ZIA CP010126-00580
|
$52,897
|
$5,290
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-23S1
|
$125,000
|
$1,250
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-23
|
$431,709
|
$4,317
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-38S1
|
$12,500
|
$125
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-38S2
|
$12,459
|
$125
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-38
|
$5,870,229
|
$58,702
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Urologic Oncology Research Training Grant
|
5T32CA082088-14
|
$266,678
|
$40,002
|
SCARDINO, PETER
|
SLOAN-KETTERING INST CAN RES
|
|
Urologic Oncology Branch Consult Core
|
ZID BC 011092
|
$2,192,713
|
$1,315,628
|
Linehan, W. Marston
|
CCR (NCI)
|
|
URINARY BIOMARKERS OF RENAL CELL CARCINOMAS
|
5R01CA141521-03
|
$296,476
|
$296,476
|
MORRISSEY, JEREMIAH
|
WASHINGTON UNIVERSITY
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-29
|
$1,065,000
|
$10,650
|
Bearden, James
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-29
|
$2,114,386
|
$148,007
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Maryland Greenebaum Cancer Center Support Grant
|
5P30CA134274-06
|
$1,463,426
|
$14,634
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Hawaii Cancer Center CCSG
|
3P30CA071789-14S1
|
$113,245
|
$1,132
|
CARBONE, MICHELE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Hawaii Cancer Center CCSG
|
3P30CA071789-14S2
|
$71,639
|
$716
|
CARBONE, MICHELE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Hawaii Cancer Center CCSG
|
5P30CA071789-14
|
$1,063,659
|
$10,637
|
CARBONE, MICHELE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-26
|
$1
|
$0
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$224,566
|
$44,913
|
Fowler, Daniel
|
CCR (NCI)
|
|
U10 Full Member Application Affiliated with SWOG
|
5U10CA105409-10
|
$341,201
|
$30,708
|
Eng, Cathy
|
UT MD ANDERSON CANCER CTR
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$336,277
|
$6,726
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Tulane Medical/Cancer Center Minority-Based Community Clinical Oncology Program
|
5U10CA167782-02
|
$663,700
|
$19,911
|
Robinson, William
|
TULANE UNIVERSITY OF LOUISIANA
|
|
Translational Surgical Pathology
|
ZIE SC 000853
|
$192,735
|
$77,094
|
Merino, Maria
|
CCR (NCI)
|
|
Translational Research in Cancer
|
2P30CA056036-14
|
$2,647,679
|
$105,907
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-14S1
|
$73,216
|
$2,929
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
|
5R01CA109446-11
|
$242,926
|
$242,926
|
Griffith, Thomas
|
UNIVERSITY OF MINNESOTA
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-30
|
$676,878
|
$6,769
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
Tissue Processing/Sequencing Core
|
ZIC BC 011044
|
$404,912
|
$202,456
|
Vocke, Cathy
|
CCR (NCI)
|
|
Tissue Array Research Program
|
ZIC BC 010923
|
$527,328
|
$26,366
|
Hewitt, Stephen
|
CCR (NCI)
|
|
Therapeutic use of immunomodulators and ionizining radiation
|
ZIA BC 011455
|
$113,412
|
$37,426
|
Haglund, Karl
|
CCR (NCI)
|
|
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen Sensing
|
5R01CA068490-18
|
$274,747
|
$274,747
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INST
|
|
The UT MD Anderson Cancer Center Community Clinical Oncology Program Research Bas
|
5U10CA045809-25
|
$1,885,277
|
$18,853
|
FISCH, MICHAEL
|
UT MD ANDERSON CANCER CTR
|
|
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy
|
5R01CA166105-02
|
$318,902
|
$63,780
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression
|
4R00CA149178-03
|
$234,060
|
$58,515
|
Dan, Hancai
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
The Role of Fgf Signaling in Vertebrate Development
|
ZIA BC 010338
|
$282,062
|
$56,412
|
Lewandoski, Mark
|
CCR (NCI)
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
2P30CA060553-19
|
$4,635,678
|
$46,357
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-19S1
|
$75,000
|
$750
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-19S2
|
$50,000
|
$500
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
3R01CA079830-12S1
|
$64,824
|
$64,824
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
5R01CA079830-12
|
$300,984
|
$300,984
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S3
|
$501,282
|
$5,013
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S4
|
$122,789
|
$1,228
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-07S1
|
$125,000
|
$1,250
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
5U10CA114671-07
|
$362,718
|
$3,627
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
Total relevant funding to Kidney Cancer for this search: $45,589,825
|